中国卵巢癌疾病负担现状及趋势分析

doi:10.12280/gjfckx.20211193

摘要/Abstract

摘要：

目的： 分析1990—2019年中国卵巢癌疾病负担现状及变化趋势,为卵巢癌的防控提供科学依据。方法： 用2019年全球疾病负担（Global Burden of Disease 2019,GBD 2019）数据,收集1990—2019年中国、美国、俄罗斯、日本、印度和全球女性卵巢癌的标化患病率、标化发病率、标化死亡率和标化伤残调整生命年（disability adjusted life year,DALY）率,对比分析中国女性卵巢癌情况。结果： 1990—2019年中国卵巢癌4项指标均呈显著增长趋势,标化患病率从1990年的10.11/10万上升至2019年的20.44/10万,标化发病率从2.56/10万上升至4.54/10万,标化死亡率1.76/10万上升至2.77/10万,标化DALY率从55.57/10万上升至80.52/10万。相较于全球总体情况及纳入分析的其他4个国家,2019年中国卵巢癌4项指标水平均较低,但近30年间中国的3项指标（标化患病率、标化发病率、标化死亡率）增幅均最大,分别为202.18%、177.34%和157.39%。结论： 1990—2019年中国卵巢癌疾病负担呈大幅增长趋势,应采取相关措施予以重视预防与控制。

关键词: 卵巢肿瘤, 患病率, 发病率, 死亡率, 卫生服务研究, 全球疾病负担, 伤残调整生命年

Abstract:

Objective: To analyze current status and trend of ovarian cancer burden in China from 1990 to 2019, in order to provide scientific basis for prevention and control of ovarian cancer. Methods: Global burden of disease (GBD) 2019 data were used to collect the standardized rate of prevalence (SPR), incidence (SIR), mortality (SMR), and disability adjusted life year (DALY) of ovarian cancer in China. The US, Russia, Japan, India, and Global from 1990 to 2019, so as to comparative analysis the ovarian cancer situation in Chinese women. Results: From 1990 to 2019, all four indicators of ovarian cancer in China showed a significant rising trend, with the SPR increasing from 10.11/100 000 in 1990 to 20.44/100 000 in 2019, the SIR increasing from 2.56/100 000 to 4.54/100 000 and the SMR increasing from 1.76/100 000 to 2.77/100 000 and the standardized DALY rate increased from 55.57/100 000 to 80.52/100 000. Compared with the overall global situation and the four countries included in the analysis, all four indicators in China were all at the low level in 2019, but China had the largest growth in three indicators (SPR, SIR, SMR) over the past 30 years, 202.18%, 177.34%, 157.39% respectively. Conclusions: From 1990 to 2019, the disease burden of ovarian cancer in China has shown a substantial increase, it turns out that relevant measures should be taken to pay attention to prevention and control.

Key words: Ovarian neoplasms, Prevalence, Incidence, Mortality, Health services research, Global burden of disease, Disability adjusted life year

汤梓莹, 邓明港, 宇传华, 刘晴. 中国卵巢癌疾病负担现状及趋势分析[J]. 国际妇产科学杂志, 2022, 49(2): 222-227.

TANG Zi-ying, DENG Ming-gang, YU Chuan-hua, LIU Qing. Current Status and Trend Analysis of Ovarian Cancer Disease Burden in China[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 222-227.

图/表 6

参考文献 30

[1]	Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer[J]. BMJ, 2020, 371:m3773. doi: 10.1136/bmj.m3773. doi: 10.1136/bmj.m3773
[2]	World Health Organization. Global Cancer Observatory[EB/OL]. [2021-07-29]. https://gco.Iarc.fr/today/online-analysis-table.
[3]	Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. doi: 10.1016/j.bpobgyn.2016.08.006
[4]	中华人民共和国国家卫生健康委员会. 卵巢癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2019, 5(2):87-96. doi: 10.12151/JMCM.2019.02-12. doi: 10.12151/JMCM.2019.02-12
[5]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338. doi: 10.3322/caac.21338
[6]	Institute for Health Metrics and Evaluation. Global Health Data Exchange, 2019[EB/OL]. [2020-10-30]. [2021-07-30]. http://ghdx.healthdata.org/gbd-results-tool.
[7]	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. doi: 10.1016/S0140-6736(20)30925-9
[8]	秦国双, 温昊于, 宇传华. 中国COPD的患病发病及YLD现状及趋势[J]. 公共卫生与预防医学, 2019, 30(2):4-8. doi: 10.3969/j.issn.1006-2483.2019.02.002. doi: 10.3969/j.issn.1006-2483.2019.02.002
[9]	Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2016, 387(10015):251-272. doi: 10.1016/S0140-6736(15)00551-6. doi: 10.1016/S0140-6736(15)00551-6
[10]	宇传华, 崔芳芳. 全球疾病负担研究及其对我国的启示[J]. 公共卫生与预防医学, 2014, 25(2):1-5.
[11]	李茜瑶, 周莹, 黄辉, 等. 疾病负担研究进展[J]. 中国公共卫生, 2018, 34(5):777-780. doi: 10.11847/zgggws1118319. doi: 10.11847/zgggws1118319
[12]	U.S. Cancer Statistics Working Group. United States Cancer Statistics:1999-2011 Incidence and Mortality Web-based Report[R]. Atlanta:U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2014.
[13]	Zheng L, Cui C, Shi O, et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017[J]. Gynecol Oncol, 2020, 159(1):239-247. doi: 10.1016/j.ygyno.2020.07.008. doi: 10.1016/j.ygyno.2020.07.008
[14]	Sopik V, Iqbal J, Rosen B, et al. Why have ovarian cancer mortality rates declined? Part I. Incidence[J]. Gynecol Oncol, 2015, 138(3):741-749. doi: 10.1016/j.ygyno.2015.06.017. doi: 10.1016/j.ygyno.2015.06.017
[15]	Sopik V, Iqbal J, Rosen B, et al. Why have ovarian cancer mortality rates declined? Part II. Case-fatality[J]. Gynecol Oncol, 2015, 138(3):750-756. doi: 10.1016/j.ygyno.2015.06.016. doi: 10.1016/j.ygyno.2015.06.016
[16]	Sopik V, Rosen B, Giannakeas V, et al. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future[J]. Gynecol Oncol, 2015, 138(3):757-761. doi: 10.1016/j.ygyno.2015.06.019. doi: 10.1016/j.ygyno.2015.06.019
[17]	Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer[J]. Chin Clin Oncol, 2020, 9(4):47. doi: 10.21037/cco-20-34. doi: 10.21037/cco-20-34 pmid: 32648448
[18]	Logan AC, Prescott SL, Katz DL. Golden Age of Medicine 2.0: Lifestyle Medicine and Planetary Health Prioritized[J]. J Lifestyle Med, 2019, 9(2):75-91. doi: 10.15280/jlm.2019.9.2.75. doi: 10.15280/jlm.2019.9.2.75
[19]	Sakauchi F, Khan MM, Mori M, et al. Dietary habits and risk of ovarian cancer death in a large-scale cohort study (JACC study) in Japan[J]. Nutr Cancer, 2007, 57(2):138-145. doi: 10.1080/01635580701274178. doi: 10.1080/01635580701274178 pmid: 17571946
[20]	刘云嵘. 中国已婚育龄妇女避孕方法使用现状及发展变化趋向(四)[J]. 中国计划生育学杂志, 2004, 12(8):454-456. doi: 10.3969/j.issn.1004-8189.2004.08.002. doi: 10.3969/j.issn.1004-8189.2004.08.002
[21]	李玉艳, 武俊青. 我国口服避孕药的使用现状和对策[J]. 中国计划生育学杂志, 2016, 24(8):508-511.
[22]	Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group[J]. Am J Epidemiol, 1992, 136(10):1184-1203. doi: 10.1093/oxfordjournals.aje.a116427. doi: 10.1093/oxfordjournals.aje.a116427 pmid: 1476141
[23]	王军, 李向梅. 中国三孩政策下的低生育形势、人口政策困境与出路[J]. 青年探索, 2021, 4:50-61. doi: 10.13583/j.cnki.issn.1004-3780.2021.04.005. doi: 10.13583/j.cnki.issn.1004-3780.2021.04.005
[24]	Babic A, Sasamoto N, Rosner BA, et al. Association Between Breastfeeding and Ovarian Cancer Risk[J]. JAMA Oncol, 2020, 6(6):e200421. doi: 10.1001/jamaoncol.2020.0421. doi: 10.1001/jamaoncol.2020.0421
[25]	Wang Y, Zhou C. China should take more measures to raise its breastfeeding rate[J]. Biosci Trends, 2019, 13(4):358-360. doi: 10.5582/bst.2019.01240. doi: 10.5582/bst.2019.01240 pmid: 31527332
[26]	Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2. doi: 10.1016/S0140-6736(18)32552-2
[27]	李晶, 吴妙芳, 林仲秋. 《FIGO 2018妇癌报告》--卵巢癌、输卵管癌、腹膜癌诊治指南解读[J]. 中国实用妇科与产科杂志, 2019, 35(3):304-314. doi: 10.19538/j.fk2019030113. doi: 10.19538/j.fk2019030113
[28]	郎景和. 妇科恶性肿瘤筛查[J]. 中国实用妇科与产科杂志, 2016, 32(5):385-389. doi: 10.7504/fk2016040101. doi: 10.7504/fk2016040101
[29]	许廷兰, 王洲, 李团结, 等. 超声联合血清CA125、AMH、HE4在卵巢子宫内膜异位症囊肿和卵巢癌中的鉴别价值[J]. 中南医学科学杂志, 2021, 49(5):587-590. doi: 10.15972/j.cnki.43-1509/r.2021.05.022. doi: 10.15972/j.cnki.43-1509/r.2021.05.022
[30]	周琦, 吴小华, 刘继红, 等. 中国卵巢上皮性癌维持治疗专家共识(2020)[J]. 中国实用妇科与产科杂志, 2020, 36(3):234-238. doi: 10.19538/j.fk2020030113. doi: 10.19538/j.fk2020030113

年份（年）	DALY（万）	DALY率（/10万）	标化DALY率（/10万）
1990	27.51	47.96	55.57
1991	28.77	49.60	56.76
1992	29.80	50.83	57.40
1993	30.91	52.21	58.13
1994	32.42	54.23	59.31
1995	33.90	56.18	60.28
1996	35.50	58.30	61.43
1997	36.75	59.82	61.98
1998	38.53	62.16	63.20
1999	40.35	64.56	64.46
2000	42.14	66.88	65.73
2001	44.29	69.77	67.46
2002	46.30	72.43	68.99
2003	47.66	74.08	69.40
2004	49.53	76.54	70.28
2005	51.17	78.67	70.68
2006	52.49	80.29	70.56
2007	54.03	82.24	70.69
2008	55.57	84.17	70.84
2009	57.32	86.42	71.27
2010	59.53	89.36	72.14
2011	61.51	91.92	72.62
2012	63.06	93.78	72.52
2013	65.00	96.18	72.81
2014	68.65	101.09	74.88
2015	70.26	102.91	74.64
2016	71.60	104.20	74.10
2017	76.21	110.25	76.95
2018	80.56	115.96	79.44
2019	83.51	119.72	80.52

年份（年）	DALY（万）	DALY率（/10万）	标化DALY率（/10万）
1990	27.51	47.96	55.57
1991	28.77	49.60	56.76
1992	29.80	50.83	57.40
1993	30.91	52.21	58.13
1994	32.42	54.23	59.31
1995	33.90	56.18	60.28
1996	35.50	58.30	61.43
1997	36.75	59.82	61.98
1998	38.53	62.16	63.20
1999	40.35	64.56	64.46
2000	42.14	66.88	65.73
2001	44.29	69.77	67.46
2002	46.30	72.43	68.99
2003	47.66	74.08	69.40
2004	49.53	76.54	70.28
2005	51.17	78.67	70.68
2006	52.49	80.29	70.56
2007	54.03	82.24	70.69
2008	55.57	84.17	70.84
2009	57.32	86.42	71.27
2010	59.53	89.36	72.14
2011	61.51	91.92	72.62
2012	63.06	93.78	72.52
2013	65.00	96.18	72.81
2014	68.65	101.09	74.88
2015	70.26	102.91	74.64
2016	71.60	104.20	74.10
2017	76.21	110.25	76.95
2018	80.56	115.96	79.44
2019	83.51	119.72	80.52